GRELL, Peter, Pavel FABIAN, M KHOYLOU, Lenka RADOVÁ, Ondřej SLABÝ, Roman HRSTKA, Rostislav VYZULA, Marian HAJDÚCH and Marek SVOBODA. Akt expression and compartmentalization in prediction of clinical outcome in HER2-positive metastatic breast cancer patients treated with trastuzumab. International Journal of Oncology. 2012, 9 pp. ISSN 1019-6439. Available from: https://dx.doi.org/10.3892/ijo.2012.1576.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Akt expression and compartmentalization in prediction of clinical outcome in HER2-positive metastatic breast cancer patients treated with trastuzumab.
Authors GRELL, Peter, Pavel FABIAN, M KHOYLOU, Lenka RADOVÁ, Ondřej SLABÝ, Roman HRSTKA, Rostislav VYZULA, Marian HAJDÚCH and Marek SVOBODA.
Edition International Journal of Oncology, 2012, 1019-6439.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30200 3.2 Clinical medicine
Country of publisher Greece
Confidentiality degree is not subject to a state or trade secret
Impact factor Impact factor: 2.657
Doi http://dx.doi.org/10.3892/ijo.2012.1576
UT WoS 000309297900004
Keywords in English breast cancer; HER2 protein; trastuzumab; AKT1 protein; AKT2 protein; prognosis
Tags ne MU
Tags International impact, Reviewed
Changed by Changed by: Olga Křížová, učo 56639. Changed: 2/4/2015 09:46.
Abstract
Trastuzumab is effective in about half of HER2- positive breast cancer patients. The PI3K/Akt signalling pathway plays an important role in the process of primary and secondary resistance to anti-HER2 targeted therapy. We evaluated the relationship between expression, activation and subcellular localization of selected Akt isoforms and response to trastuzumab-based anti-HER2 targeted therapy in patients with HER2-positive metastatic breast cancer.
Links
MZ0MOU2005, plan (intention)Name: Funkční diagnostika zhoubných nádorů
PrintDisplayed: 2/9/2024 18:51